ERBB2 and breast carcinoma: As systemic therapies for HER2+ breast cancer have been steadily improving, it is possible that the administration of SBRT may prolong time on any individual line of systemic therapy, with a potential to yield prolonged PFS and potentially even overall survival [26,27].